Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder [Phase 4]
Phase 4 clinical trial update investigating a beta-3 agonist and an anti-muscarinic agent for Sjogren's syndrome with overactive bladder.
-
FDA approval · 2021-08-02FDA Approved: TOLTERODINE TARTRATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' Tolterodine tartrate as an original generic application.
-
CLINICAL_TRIALS trial_result · 2021-07-30Clinical Trial Update: Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence [NA]
This update reports the completion and posted results of a pivotal clinical trial evaluating eCoin for overactive bladder with urgency urina…
-
FDA approval · 2021-06-17FDA Approved: TOVIAZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for TOVIAZ (fesoterodine fumarate) submitted by Pfizer to update its labeling.
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 [Phase 3]
A Phase 3 study evaluating Dysport (abobotulinumtoxinA) for urinary incontinence due to neurogenic detrusor overactivity in adults with spin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-05-19Clinical Trial Update: Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003) [Phase 2]
Phase 2 trial update on MK0594 for overactive bladder showed safety and efficacy data.
-
FDA approval · 2021-04-30FDA Approved: TROSPIUM CHLORIDE — Original Application (Slate Run Pharmaceuticals, LLC)
The FDA approved Slate Run Pharmaceuticals' original application for trospium chloride, a generic version of the medication indicated for ov…
-
CLINICAL_TRIALS trial_result · 2021-04-26Clinical Trial Update: eCoin for OAB Feasibility Follow-on Study [NA]
A completed feasibility follow-on study of eCoin for overactive bladder and urge urinary incontinence; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-04-15Clinical Trial Update: The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides [NA]
A completed clinical trial studying the estrogen impact on female pelvic floor microbiomes and antimicrobial peptides in overactive bladder …
-
FDA approval · 2021-03-25FDA Approved: MYRBETRIQ — Original Application (Astellas Pharma US, Inc.)
FDA approves MYRBETRIQ (mirabegron) from Astellas Pharma US as the original NDA approval for overactive bladder.
-
FDA label_change · 2021-03-25FDA Approved: MYRBETRIQ — Supplemental Application (Astellas Pharma US, Inc.)
FDA has approved a supplemental application for MYRBETRIQ (mirabegron) from Astellas US, resulting in changes to the product labeling. The a…
-
FDA approval · 2021-03-25FDA Approved: SOLIFENACIN SUCCINATE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for solifenacin succinate from Ascend Laboratories, LLC. This action completes an approval proce…
-
CLINICAL_TRIALS trial_result · 2021-03-19Clinical Trial Update: Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia. [Phase 4]
Phase 4 trial update evaluating efficacy and safety of a combination therapy for overactive bladder in male patients with benign prostatic h…
-
FDA approval · 2021-03-17FDA Approved: SOLIFENACIN SUCCINATE — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application from Apotex Corp. for a generic solifenacin succinate, authorizing the generic version's approva…
-
CLINICAL_TRIALS trial_result · 2021-03-04Clinical Trial Update: A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) [Phase 3]
Phase 3 trial completed evaluating a new drug for overactive bladder; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). [Phase 3]
A Phase 3 extension study evaluated the safety and tolerability of a new drug in patients with symptoms of overactive bladder; study complet…
-
FDA approval · 2021-02-02FDA Approved: TOLTERODINE TARTRATE — Original Application (Slate Run Pharmaceuticals, LLC)
FDA approved Slate Run Pharmaceuticals' generic tolterodine tartrate under an Original Application (ANDA).
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication. [Phase 4]
Phase 4 trial evaluating Detrol LA with behavioral intervention for patients with overactive bladder who were dissatisfied with prior OAB me…
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women [Phase 4]
Phase 4 trial update evaluating Detrol LA effects on overactive bladder symptoms, sexual quality of life, and sexual function in women.
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder [Phase 4]
Phase 4 trial assessing the effect of tolterodine extended release on bladder wall thickness in patients with urinary incontinence.
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction [Phase 4]
A Phase 4 trial assessing the effect and safety of Detrol LA in men with overactive bladder symptoms, with or without bladder outlet obstruc…
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder. [Phase 4]
Phase 4 study evaluating tolterodine on specific symptoms in adults with overactive bladder; study completed.
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Detrol LA In Men With Overactive Bladder. [Phase 4]
Phase 4 clinical trial update for Detrol LA in men with overactive bladder, completed.
-
FDA approval · 2021-01-25FDA Approved: SOLIFENACIN SUCCINATE — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for solifenacin succinate from Unichem Pharmaceuticals (USA), Inc.
-
FDA approval · 2021-01-14FDA Approved: SOLIFENACIN SUCCINATE — Supplemental Application (Bostal LLC)
FDA approved a supplemental application for solifenacin succinate submitted by Bostal LLC.